Orthopedia Stock Price, News & Analysis

OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will present at the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:00 PM ET. The company specializes in pediatric orthopedics, offering 39 surgical systems across trauma, deformity, scoliosis, and sports medicine categories. Interested parties can access the live webcast and archived presentation via the OrthoPediatrics website. Founded in 2006, the company is dedicated to improving the lives of children with orthopedic conditions, and distributes its products in the USA and 70 other countries.

OrthoPediatrics Corp. (Nasdaq: KIDS) has successfully closed its public offering of 1,091,250 shares at $55.00 each and pre-funded warrants for 1,525,000 shares at $54.99975. This transaction generated gross proceeds of approximately $144 million. The largest investor, Squadron Capital LLC, purchased the pre-funded warrants, which must be exercised upon meeting specific conditions. The net proceeds will support investments in equipment, R&D, debt repayment, and marketing efforts.

OrthoPediatrics Corp. (KIDS) announced the pricing of a public offering of 750,000 shares of common stock at $55.00 per share, alongside pre-funded warrants for an additional 1,525,000 shares. The total expected gross proceeds are approximately $125 million. These funds will be used for expanding product offerings, repaying debt, supporting R&D, and enhancing sales and marketing efforts. The offering is set to close around August 15, 2022, pending customary conditions.

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced an underwritten public offering of its common stock and pre-funded warrants to purchase shares. The offering, managed by Piper Sandler and Stifel, includes a 30-day option for underwriters to purchase additional shares. Proceeds will support investments in implant and instrument sets, long-term debt repayment, research and development, and sales expansion. The securities are offered under a shelf registration statement effective since March 2020, with no assurance on completion timing due to market conditions.

OrthoPediatrics Corp. (KIDS) reported a record revenue of $32.9 million for Q2 2022, marking a 23% year-over-year increase. The company helped over 23,000 children, raising the total to 560,000. Adjusted EBITDA reached $2.1 million, up from $1.2 million in Q2 2021. Revenue from Trauma & Deformity grew 26%, while Scoliosis revenue increased 23%. The company raised its full-year revenue guidance to $127-$130 million, reflecting a 30%-33% growth compared to 2021.

OrthoPediatrics Corp. (NASDAQ: KIDS) is set to release its second quarter 2022 financial results on August 3, 2022, post-market. A conference call will follow on August 4, 2022, at 8:00 a.m. ET, to discuss these results. OrthoPediatrics specializes in pediatric orthopedics, offering 39 surgical systems across trauma, scoliosis, and sports medicine categories. The company's products are marketed in the U.S. and 70 additional countries, reflecting its extensive global reach.

OrthoPediatrics Corp. (Nasdaq: KIDS) has entered into an exclusive distribution agreement with 3D-Side S.A. to distribute the 3D-CUT-OSTEO osteotomy guide in leading pediatric hospitals in the U.S. and select international markets. This innovative technology utilizes patient-specific 3D printed cutting guides, enhancing surgical precision for corrective procedures and tumor resections. OrthoPediatrics aims to complement its offerings in pediatric orthopedics by increasing its presence in the pediatric oncology market, addressing complex treatment needs.

OrthoPediatrics Corp. (KIDS) announced its acquisition of Pega Medical for $33 million, consisting of $31 million cash and $2 million in stock with restrictions. This acquisition enhances OrthoPediatrics' product offerings aimed at addressing pediatric musculoskeletal disorders. Pega's innovations, such as the Fassier-Duval Telescopic Intramedullary System™, are designed for treating conditions like Osteogenesis Imperfecta. Additionally, OrthoPediatrics raised its 2022 revenue guidance to $125-$128 million, reflecting a growth of 27%-31%.

OrthoPediatrics Corp. (Nasdaq: KIDS) announced an agreement to acquire Pega Medical for up to $33 million, enhancing its pediatric orthopedic portfolio. The deal includes a $31 million cash payment and $2 million in stock. OrthoPediatrics plans to finance the acquisition using an expanded credit facility of $50 million. The company also raised its full-year 2022 revenue guidance to a range of $125 million to $128 million, reflecting a 27% to 31% growth. This acquisition aims to better address needs in treating children with conditions like osteogenesis imperfecta.